anmelden
Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024
Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024
Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held an Extraordinary General Meeting on July 24, 2024. The shareholders approved all items on the agenda of the Extraordinary General Meeting.
All documents pertaining to the Extraordinary General Meeting held on July 24, 2024, can be consulted on Oxurion’s website Oxurion/shareholders.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.
Please contact for additional information:
|
Oxurion NV Pascal Ghoson Chief Executive Officer pascal.ghoson@oxurion.com |
Attachments
Ausgewählte Hebelprodukte auf ThromboGenics NV
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf ThromboGenics NV
Der Hebel muss zwischen 2 und 20 liegen
